🚀 VC round data is live in beta, check it out!
Protalix Valuation Multiples
Discover revenue and EBITDA valuation multiples for Protalix and similar public comparables like MediWound, Century Therapeutics, Hyloris Pharmaceuticals, BGM Group and more.
Protalix Overview
About Protalix
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
Founded
1992
HQ
Employees
213
Website
Sectors
Financials (LTM)
EV
$202M
Protalix Financials
Protalix reported last 12-month revenue of $60M.
In the same LTM period, Protalix generated $35M in gross profit and had net loss of ($437K).
Revenue (LTM)
Protalix P&L
In the most recent fiscal year, Protalix reported revenue of $53M and EBITDA of ($3M).
Protalix expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $60M | XXX | $53M | XXX | XXX | XXX |
| Gross Profit | $35M | XXX | $26M | XXX | XXX | XXX |
| Gross Margin | 58% | XXX | 49% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($3M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (6%) | XXX | XXX | XXX |
| EBIT Margin | 1% | XXX | (10%) | XXX | XXX | XXX |
| Net Profit | ($437K) | XXX | ($7M) | XXX | XXX | XXX |
| Net Margin | (1%) | XXX | (13%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Protalix Stock Performance
Protalix has current market cap of $224M, and enterprise value of $202M.
Market Cap Evolution
Protalix's stock price is $2.78.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $202M | $224M | 0.0% | XXX | XXX | XXX | $-0.08 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialProtalix Valuation Multiples
Protalix trades at 3.4x EV/Revenue multiple, and (68.6x) EV/EBITDA.
EV / Revenue (LTM)
Protalix Financial Valuation Multiples
As of April 6, 2026, Protalix has market cap of $224M and EV of $202M.
Equity research analysts estimate Protalix's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Protalix has a P/E ratio of (511.5x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $224M | XXX | $224M | XXX | XXX | XXX |
| EV (current) | $202M | XXX | $202M | XXX | XXX | XXX |
| EV/Revenue | 3.4x | XXX | 3.8x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (68.6x) | XXX | XXX | XXX |
| EV/EBIT | 433.6x | XXX | (36.8x) | XXX | XXX | XXX |
| EV/Gross Profit | 5.9x | XXX | 7.9x | XXX | XXX | XXX |
| P/E | (511.5x) | XXX | (33.9x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (14.8x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Protalix Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Protalix Margins & Growth Rates
Protalix's revenue in the last 12 month grew by 28%.
Protalix's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Protalix Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 28% | XXX | 50% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (6%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (145%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 37% | XXX | 37% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 59% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Protalix Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| MediWound | XXX | XXX | XXX | XXX | XXX | XXX |
| Century Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Hyloris Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| BGM Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Voyager Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Protalix M&A Activity
Protalix acquired XXX companies to date.
Last acquisition by Protalix was on XXXXXXXX, XXXXX. Protalix acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Protalix
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialProtalix Investment Activity
Protalix invested in XXX companies to date.
Protalix made its latest investment on XXXXXXXX, XXXXX. Protalix invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Protalix
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Protalix
| When was Protalix founded? | Protalix was founded in 1992. |
| Where is Protalix headquartered? | Protalix is headquartered in United States. |
| How many employees does Protalix have? | As of today, Protalix has over 213 employees. |
| Who is the CEO of Protalix? | Protalix's CEO is Dror Bashan. |
| Is Protalix publicly listed? | Yes, Protalix is a public company listed on NYSE American. |
| What is the stock symbol of Protalix? | Protalix trades under PLX ticker. |
| When did Protalix go public? | Protalix went public in 1996. |
| Who are competitors of Protalix? | Protalix main competitors are MediWound, Century Therapeutics, Hyloris Pharmaceuticals, BGM Group. |
| What is the current market cap of Protalix? | Protalix's current market cap is $224M. |
| What is the current revenue of Protalix? | Protalix's last 12 months revenue is $60M. |
| What is the current revenue growth of Protalix? | Protalix revenue growth (NTM/LTM) is 28%. |
| What is the current EV/Revenue multiple of Protalix? | Current revenue multiple of Protalix is 3.4x. |
| Is Protalix profitable? | No, Protalix is not profitable. |
| What is the current net income of Protalix? | Protalix's last 12 months net income is ($437K). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.